A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

NCT06577025 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Cilta-cel
DRUG: Talquetamab
DRUG: Daratumumab
DRUG: Teclistamab
DRUG: Bortezomib
DRUG: Lenalidomide
DRUG: Dexamethasone
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

Janssen Research & Development, LLC